Insider buying
~$40K25K sh @ $1.60
Traded Nov 13 · filed the same day
The CEO of Lipocine paid $40K out of pocket for Lipocine shares. Shares held went up 13% with this purchase.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 12, 2026 · Filed Nov 13, 2026
The CEO of Lipocine paid $39K out of pocket for Lipocine shares. It was the first purchase in 7 months. Shares held went up 16% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$39,490
Shares × reported transaction price
$25K–$100K
+15.5%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 7 months
Confirmed open-market purchases by the same insider in the available history
No
Compared with 2 earlier confirmed purchases
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals about 4% of the CEO's reported total pay for fiscal 2025 ($986K)
Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-04-21. The proxy names Mahesh Patel as CEO for that year. A size comparison, not a judgement
7 days after results of Nov 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $1.62 on Nov 12, 2026, 13% above its 52-week low and 86% below its high, after a 22% drop over the previous 30 trading days
52-week range $1.44 (Oct 23, 2026) to $11.26 (Jan 15, 2026), 2% of the way up, from 251 adjusted closes. 30 trading days earlier: $2.07 on Oct 1, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Insider buying
Traded Nov 13 · filed the same day
The CEO of Lipocine paid $40K out of pocket for Lipocine shares. Shares held went up 13% with this purchase.
Insider buying
Traded Sep 29 · filed 3 days later
A Lipocine director paid $19K out of pocket for Lipocine shares.
Insider buying
Traded Sep 30 · filed 2 days later
A Lipocine director paid $36K out of pocket for Lipocine shares. Shares held went up 7% with this purchase.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.